Is it time for a new yellow fever vaccine?
An inexpensive live attenuated vaccine (the 17D vaccine) against yellow fever has been effectively used to prevent yellow fever for more than 70 years. Interest in developing new inactivated vaccines has been spurred by recognition of rare but serious, sometimes fatal adverse events following live virus vaccination. A safer inactivated yellow fever vaccine could be useful for vaccinating people at higher risk of adverse events from the live vaccine, but could also have broader global health utility by lowering the risk-benefit threshold for assuring high levels of yellow fever vaccine coverage. If ongoing trials demonstrate favorable immunogenicity and safety compared to the current vaccine, the practical global health utility of an inactivated vaccine is likely to be determined mostly by cost.
Barcelona Centre for International Health Research, Rosselo 132, 08036 Barcelona, Spain. ned.hayes@cresib.cat
Edward B
EB
Hayes
D006801:Humans; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000191:economics / Q000276:immunology; D022341:Yellow Fever Vaccine / Q000009:adverse effects* / Q000191:economics / Q000276:immunology*
D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D022341:Yellow Fever Vaccine